Catalent will assess Jupiter Orphan Therapeutics’ resveratrol across its softgel technologies in an effort to improve the bioavailability of the rare disease candidate.
Despite requiring more API, the price of inhaled insulin Afrezza has dropped below that of injected rapid-acting rivals says MannKind's CEO, reporting a resilient Q3.
Saneca Pharma will invest in its manufacturing site in Slovakia to service a five-year agreement supplying the Menarini Group with controlled release pellets.
Capsugel has come on leaps-and-bounds since it was spun-out from Pfizer, the firm says as it inks a deal with Pulmatrix to develop inhaled therapeutics.
MannKind has spoken about Receptor Life Science, a newly-formed company which last month licensed the Technosphere inhaled delivery platform from the struggling firm.
Catalent will pursue strategic acquisitions and licensing in 2016, said VP Marketing & Strategy Elliott Berger, noting growth areas include complex delivery technologies and specialised logistics.
MIT engineers have designed a new hydrogel material that can incorporate temperature sensors, LED lights, and other electronics – in addition to drug-delivering reservoirs.
